{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:00:36Z","timestamp":1785477636411,"version":"3.56.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma and infections remain a substantial global health problem for which no curative therapy exists. As cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T lymphocytes are the principal effectors of natural HBV resolution, there is considerable interest in identification of HBV epitopes that are presented for immune recognition. Current knowledge of HBV-derived peptide presentation to CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells is largely dominated human leukocyte antigen (HLA)-A*02:01. Our aim was to characterize novel HBV-derived peptides presented on HLA-B and -C molecules, particularly allotypes that are prevalent in regions with high HBV infection rates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To discover new HBV-derived peptides, immunopeptidomic analysis was performed on cells expressing single HLA class I molecules transduced to express individual HBV proteins. Peptide binding assays were used to validate HLA binding of selected peptides. Additionally, we used immunopeptidomic analysis to determine the effect of the recently discovered major histocompatibility complex class I (MHC-I) peptide editor TAPBPR on presentation of HBV-derived peptides. The results were validated using TAPBPR peptide-exchange assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 28 novel HBV-derived peptides presented on HLA class I. Importantly, 22 of the newly discovered HBV-derived peptides were identified on cells expressing HLA-B*08:01, -B*15:03, -B*35:01, -C*06:02 and -C*12:03.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      This work presents a substantial expansion of the HLA-B and HLA-C-restricted HBV-derived peptides described in the Immune Epitope Database (IEDB). Additionally, TAPBPR\n                      <jats:sup>KO<\/jats:sup>\n                      HeLa cells presented four additional and novel HBV-derived peptides, representing the first indication that TAPBPR shapes not only the cellular but also the viral peptide repertoire presented on MHC-I molecules.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1892820","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:37:43Z","timestamp":1785476263000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of novel HLA class I-restricted hepatitis B virus peptides and their modulation by peptide editor TAPBPR"],"prefix":"10.3389","volume":"17","author":[{"given":"Ricky","family":"Sinharay","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Cambridge","place":["Cambridge, United Kingdom"]},{"name":"Cambridge Liver Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic S.","family":"Nolan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cambridge","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bauer","sequence":"additional","affiliation":[{"name":"Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital","place":["T\u00fcbingen, Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen","place":["Tubingen, Germany"]},{"name":"German Cancer Consortium Deutsches Konsortium f\u00fcr Translationale Krebsforschung (DKTK), Partner Site T\u00fcbingen, a Partnership Between Deutsches Krebsforschungszentrum (DKFZ) and University Hospital T\u00fcbingen","place":["Tubingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neerincx","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cambridge","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[{"name":"Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital","place":["T\u00fcbingen, Germany"]},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen","place":["Tubingen, Germany"]},{"name":"German Cancer Consortium Deutsches Konsortium f\u00fcr Translationale Krebsforschung (DKTK), Partner Site T\u00fcbingen, a Partnership Between Deutsches Krebsforschungszentrum (DKFZ) and University Hospital T\u00fcbingen","place":["Tubingen, Germany"]},{"name":"Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Gelson","sequence":"additional","affiliation":[{"name":"Cambridge Liver Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwen F.","family":"Altenburg","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cambridge","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise H.","family":"Boyle","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cambridge","place":["Cambridge, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","volume-title":"Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries","year":"2024"},{"key":"B2","unstructured":"Globocan 2022 (Version 1.1) - 08.02.2024\n          \n          2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2016.06.006","article-title":"Epidemiology of hepatitis B virus infection and impact of vaccination on disease","volume":"20","author":"Nelson","year":"2016","journal-title":"Clin Liver Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Collaborators","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyi206","article-title":"A mathematical model to estimate global hepatitis B disease burden and vaccination impact","volume":"34","author":"Goldstein","year":"2005","journal-title":"Int J Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection","volume":"24","author":"McMahon","year":"2004","journal-title":"Semin Liver Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61412-x","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.013","article-title":"Battlefield against hepatitis B infection and HCC in Africa","volume":"66","author":"Lemoine","year":"2017","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0296-6","article-title":"The evolution and clinical impact of hepatitis B virus genome diversity","volume":"17","author":"Revill","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12885-022-09413-7","article-title":"Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/s2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/jvi.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.5009\/gnl17233","article-title":"Immunotherapy for chronic hepatitis B virus infection","volume":"12","author":"Bertoletti","year":"2018","journal-title":"Gut Liver"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(88)80503-8","article-title":"Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection","volume":"145","author":"Ferrari","year":"1990","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.6.1565","article-title":"Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen","volume":"174","author":"Penna","year":"1991","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.10.4659","article-title":"HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection","volume":"150","author":"Nayersina","year":"1993","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.3.1047","article-title":"The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis","volume":"181","author":"Rehermann","year":"1995","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-51709-0_16","article-title":"HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen","volume":"88","author":"Bertoletti","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198264","article-title":"Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides","volume":"13","author":"Yamamiya","year":"2018","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/gutjnl-2018-316644","article-title":"Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection","volume":"68","author":"Hoogeveen","year":"2019","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01663-19","article-title":"Discovery and selection of hepatitis B virus-derived T cell epitopes for global immunotherapy based on viral indispensability, conservation, and HLA-binding strength","volume":"94","author":"de Beijer","year":"2020","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020257","article-title":"A systematic review of T cell epitopes defined from the proteome of hepatitis B virus","volume":"10","author":"Wu","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301507","article-title":"Defining CD8+ T cell determinants during human viral infection in populations of Asian ethnicity","volume":"191","author":"Rivino","year":"2013","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1006","article-title":"The immune epitope database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01124-08","article-title":"Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire","volume":"82","author":"Tan","year":"2008","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02600-13","article-title":"Immunoprevalence and immunodominance of HLA-Cw*0801-restricted T cell response targeting the hepatitis B virus envelope transmembrane region","volume":"88","author":"Tan","year":"2014","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz1029","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80487-2","article-title":"Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP","volume":"5","author":"Sadasivan","year":"1996","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5330.1306","article-title":"A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes","volume":"277","author":"Ortmann","year":"1997","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00304-7","article-title":"Optimization of the MHC class I peptide cargo is dependent on tapasin","volume":"16","author":"Williams","year":"2002","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601624","article-title":"Analysis of interactions in a tapasin\/class I complex provides a mechanism for peptide selection","volume":"26","author":"Chen","year":"2007","journal-title":"EMBO J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/79775","article-title":"Impaired immune responses and altered peptide repertoire in tapasin-deficient mice","volume":"1","author":"Garbi","year":"2000","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)00021-2","article-title":"Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice","volume":"13","author":"Grandea","year":"2000","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4049\/jimmunol.0803489","article-title":"Absence of tapasin alters immunodominance against a lymphocytic choriomeningitis virus polytope","volume":"184","author":"Boulanger","year":"2010","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222342110","article-title":"Tapasin-related protein TAPBPR is an additional component of the MHC class I presentation pathway","volume":"110","author":"Boyle","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300929","article-title":"The binding of TAPBPR and Tapasin to MHC class I is mutually exclusive","volume":"191","author":"Hermann","year":"2013","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7554\/elife.09617","article-title":"TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst","volume":"4","author":"Hermann","year":"2015","journal-title":"Elife"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519894113","article-title":"Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing","volume":"113","author":"Morozov","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7554\/elife.23049","article-title":"TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway","volume":"6","author":"Neerincx","year":"2017","journal-title":"Elife"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7554\/elife.85432","article-title":"The ER folding sensor UGGT1 acts on TAPBPR-chaperoned peptide-free MHC I","volume":"12","author":"Sagert","year":"2023","journal-title":"Elife"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao5154","article-title":"Crystal structure of a TAPBPR-MHC I complex reveals the mechanism of peptide editing in antigen presentation","volume":"358","author":"Jiang","year":"2017","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao6001","article-title":"Structure of the TAPBPR-MHC I complex defines the mechanism of peptide loading and editing","volume":"358","author":"Thomas","year":"2017","journal-title":"Science"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1039\/d2cp00423b","article-title":"Dynamics of peptide loading into major histocompatibility complex class I molecules chaperoned by TAPBPR","volume":"24","author":"Xu","year":"2022","journal-title":"Phys Chem Chem Phys"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.7554\/elife.55326","article-title":"A loop structure allows TAPBPR to exert its dual function as MHC I chaperone and peptide editor","volume":"9","author":"Sagert","year":"2020","journal-title":"Elife"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7554\/elife.40126","article-title":"TAPBPR mediates peptide dissociation from MHC class I using a leucine lever","volume":"7","author":"Ilca","year":"2018","journal-title":"Elife"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1038\/s41467-021-23225-6","article-title":"TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap","volume":"12","author":"McShan","year":"2021","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12688\/wellcomeopenres.20738.2","article-title":"Reanalysis of immunopeptidomics datasets provides mechanistic insight into TAPBPR-mediated peptide editing on HLA-A, -B and -C molecules","volume":"9","author":"Altenburg","year":"2024","journal-title":"Wellcome Open Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1809465115","article-title":"Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules","volume":"115","author":"Ilca","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.09.074","article-title":"Distinct polymorphisms in HLA class I molecules govern their susceptibility to peptide editing by TAPBPR","volume":"29","author":"Ilca","year":"2019","journal-title":"Cell Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1987.tb02659.x","article-title":"Functional equivalents of interferon-mediated signals needed for induction of an mRNA can be generated by double-stranded RNA and growth factors","volume":"6","author":"Tiwari","year":"1987","journal-title":"EMBO J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.molimm.2018.06.269","article-title":"Preferential interaction of MHC class I with TAPBPR in the absence of glycosylation","volume":"113","author":"Neerincx","year":"2019","journal-title":"Mol Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9450-2_10","article-title":"Purification and identification of naturally presented MHC class I and II ligands","volume":"1988","author":"Nelde","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1316438","article-title":"HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy","volume":"7","author":"Nelde","year":"2018","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/1044-0305(94)80016-2","article-title":"An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database","volume":"5","author":"Eng","year":"1994","journal-title":"J Am Soc Mass Spectrom"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth1113","article-title":"Semi-supervised learning for peptide identification from shotgun proteomics datasets","volume":"4","author":"Kall","year":"2007","journal-title":"Nat Methods"},{"key":"B63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-60327-118-9_5","article-title":"SYFPEITHI: database for searching and T-cell epitope prediction","volume":"409","author":"Schuler","year":"2007","journal-title":"Methods Mol Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2649-2","article-title":"Array programming with numpy","volume":"585","author":"Harris","year":"2020","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.25080\/Majora-92bf1922-00a","article-title":"Data structures for statistical computing in Python","author":"McKinney","year":"2010"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1109\/mcse.2007.55","article-title":"Matplotlib: A 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Computing In Sci And Eng"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","article-title":"seaborn: statistical data visualization","volume":"6","author":"Waskom","year":"2021","journal-title":"J Open Source Software"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz921","article-title":"Logomaker: beautiful sequence logos in Python","volume":"36","author":"Tareen","year":"2020","journal-title":"Bioinformatics"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae241","article-title":"The EMBL-EBI Job Dispatcher sequence analysis tools framework in 2024","volume":"52","author":"Madeira","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"11344","DOI":"10.1038\/s41598-020-68226-5","article-title":"Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients","volume":"10","author":"Chua","year":"2020","journal-title":"Sci Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.8.5582-5591.1996","article-title":"Proteasome complex as a potential cellular target of hepatitis B virus X protein","volume":"70","author":"Huang","year":"1996","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.73.9.7231-7240.1999","article-title":"Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex","volume":"73","author":"Hu","year":"1999","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m910378199","article-title":"Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex","volume":"275","author":"Zhang","year":"2000","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1515\/bc.2003.005","article-title":"Hepatitis B virus HBx peptide 116-138 and proteasome activator PA28 compete for binding to the proteasome alpha4\/MC6 subunit","volume":"384","author":"Stohwasser","year":"2003","journal-title":"Biol Chem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.3.503","article-title":"Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes","volume":"191","author":"Sijts","year":"2000","journal-title":"J Exp Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2017.12.002","article-title":"The use of proteomics to understand antiviral immunity","volume":"84","author":"Woon","year":"2018","journal-title":"Semin Cell Dev Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(94)90462-6","article-title":"Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules","volume":"78","author":"Rock","year":"1994","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.10.001","article-title":"Peptidases trimming MHC class I ligands","volume":"25","author":"Weimershaus","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2320879121","article-title":"Principles of peptide selection by the transporter associated with antigen processing","volume":"121","author":"Lee","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903712","article-title":"Endoplasmic reticulum aminopeptidase associated with antigen processing defines the composition and structure of MHC class I peptide repertoire in normal and virus-infected cells","volume":"184","author":"Blanchard","year":"2010","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.09.005","article-title":"Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses","volume":"25","author":"Yewdell","year":"2006","journal-title":"Immunity"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load","volume":"68","author":"Schuch","year":"2019","journal-title":"Gut"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.17.8609-8620.2002","article-title":"Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections","volume":"76","author":"Kakimi","year":"2002","journal-title":"J Virol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.11.5707-5719.2004","article-title":"Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy","volume":"78","author":"Webster","year":"2004","journal-title":"J Virol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1685705","article-title":"TAPBPR promotes editing of the HLA-B44 peptide repertoire, increasing the presentation of peptides containing a C-terminal tryptophan","volume":"16","author":"Aflalo","year":"2025","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900795","article-title":"MHC-E-restricted CD8(+) T cells target hepatitis B virus-infected human hepatocytes","volume":"204","author":"Burwitz","year":"2020","journal-title":"J Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1011","article-title":"The PRIDE database at 20 years: 2025 update","volume":"53","author":"Perez-Riverol","year":"2025","journal-title":"Nucleic Acids Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1892820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:37:49Z","timestamp":1785476269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1892820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2026.1892820"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1892820","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1892820"}}